Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer’s Disease Research at The 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TOKYO, Nov 21, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. will present the efficacy, safety and biomarker findings from the company’s Phase 3 confirmatory Clarity AD clinical trial for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the potential treatment of mild cognitive impairment (MCI) due to Alzheimer’s […]

Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

TOKYO, Sep 28, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to […]